Abbisko signs $70M upfront deal with Merck KGaA for PhIII cancer drug
Shanghai-based Abbisko Therapeutics has lined up another partner for its oncology pipeline and will receive $70 million upfront as Merck KGaA grabs commercialization rights to the biotech’s lead asset in China.
Merck KGaA will dish out up to $605.5 million total, plus double-digit percentage royalties on potential future net sales, to nab commercialization rights to Abbisko’s oral small molecule pimicotinib, which is being studied in a global Phase III for patients with tenosynovial giant cell tumor, or TGCT.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.